Exhibit 107
Calculation of Filing Fee Tables
424(b)(5)
(Form Type)
Travere Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered |
Proposed Maximum Offering Price Per Share |
Maximum Aggregate Offering Price |
Fee Rate | Amount
of Registration Fee(1) | |||||||||
|
Fees to be Paid |
Equity | Common stock, par value $0.0001 per share |
Rule 457(r) | 10,953,750(2) | $21.00 | $230,028,750 | $110.20 per $1,000,000 |
$25,350 | ||||||||
|
Fees to be Paid |
Equity | Pre-funded warrants to purchase common stock |
Rule 457(r) | 1,250,000 | $21.00(3) | —(3) | $110.20 per $1,000,000 |
—(3) | ||||||||
| Total Offering Amounts | — | $230,028,750 | — | $25,350 | ||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||
| Total Fee Offsets | — | — | ||||||||||||||
| Net Fee Due | — | $25,350 | ||||||||||||||
| (1) | Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). Payment of the registration fee at the time of filing of the registrant’s Registration Statement on Form S-3 (File No. 333-259311) on September 3, 2021 was deferred pursuant to Rules 456(b) and 457(r) under the Securities Act and is paid herewith. |
| (2) | Includes 1,428,750 shares of common stock that the underwriters have an option to purchase and 1,250,000 shares of common stock that are issuable upon the exercise of the pre-funded warrants referenced below. |
| (3) | Represents the sum of the pre-funded warrants sales price of $20.9999 per pre-funded warrant and the exercise price of $0.0001 per share issuable pursuant to the pre-funded warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the pre-funded warrants. |